GRI Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

GRI Bio Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerGRI

Market Cap3.6M

Cash RunwayRunway 6-12 months

Next Catalyst2037-11

Public Research Snapshot

GRI Bio Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Quadrivalent influenza modRNA vaccine in Influenza, Human (Phase 3) using Vaccine.

Pipeline

Asset	Indication	Modality	Stage	Public Note
Who We Are	n/a	n/a	n/a	Public pipeline row
NKT SCIENCE	n/a	n/a	n/a	Public pipeline row
Quadrivalent influenza modRNA vaccine	Influenza, Human	Vaccine	Phase 3	Public pipeline row
Tazarotene (GRI-0621)	Idiopathic Pulmonary Fibrosis \| IPF	n/a	Phase 2	Public pipeline row
RSVt vaccine	RSV Immunization	Vaccine	Phase 3	Public pipeline row
Active Comparator:4.5mg GRI-0621	Chronic Liver Disease	n/a	Phase 2	Public pipeline row
Epcoritamab	Follicular Lymphoma (FL)	n/a	Phase 3	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2037-11	Epcoritamab	Low

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT02949375	Phase 2	TERMINATED	14	2018-11
NCT05540522	Phase 3	COMPLETED	45789	2024-03-12
NCT06397768	Phase 3	TERMINATED	2226	2025-09-18
NCT06331624	Phase 2	COMPLETED	35	2025-09-30
NCT06191744	Phase 3	RECRUITING	1095	2037-11

Scientific Context

literature_publication | Breaking with convention: the role of lymphocytes in IPF.
asset_name | Active Comparator:4.5mg GRI-0621
clinical_stage | Phase 2
clinical_stage | Phase 2
indication | Chronic Liver Disease

Want the full GRI research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.